Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome.
de Kruijff IE, Timmermans AM, den Bakker MA, Trapman-Jansen AMAC, Foekens R, Meijer-Van Gelder ME, Oomen-de Hoop E, Smid M, Hollestelle A, van Deurzen CHM, Foekens JA, Martens JWM, Sleijfer S. de Kruijff IE, et al. Among authors: van deurzen chm. Cancers (Basel). 2018 May 5;10(5):134. doi: 10.3390/cancers10050134. Cancers (Basel). 2018. PMID: 29734758 Free PMC article.
mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.
Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van Galen A, de Weerd V, Kraan J, van der Spoel P, Ramírez-Moreno R, van Deurzen CH, Smid M, Yu JX, Jiang J, Wang Y, Gratama JW, Sleijfer S, Foekens JA, Martens JW. Sieuwerts AM, et al. Clin Cancer Res. 2011 Jun 1;17(11):3600-18. doi: 10.1158/1078-0432.CCR-11-0255. Epub 2011 Apr 19. Clin Cancer Res. 2011. PMID: 21505063
Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell response.
Liu NQ, De Marchi T, Timmermans AM, Beekhof R, Trapman-Jansen AM, Foekens R, Look MP, van Deurzen CH, Span PN, Sweep FC, Brask JB, Timmermans-Wielenga V, Debets R, Martens JW, Foekens JA, Umar A. Liu NQ, et al. Mol Cell Proteomics. 2014 Jul;13(7):1814-27. doi: 10.1074/mcp.M113.037176. Epub 2014 Apr 17. Mol Cell Proteomics. 2014. PMID: 24742827 Free PMC article.
Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.
Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens JW, O'Connor MJ, Vrieling H, Hoeijmakers JH, Jonkers J, Kanaar R, de Winter JP, Vreeswijk MP, Jager A, van Gent DC. Naipal KA, et al. Clin Cancer Res. 2014 Sep 15;20(18):4816-26. doi: 10.1158/1078-0432.CCR-14-0571. Epub 2014 Jun 24. Clin Cancer Res. 2014. PMID: 24963051
Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.
Massink MP, Kooi IE, van Mil SE, Jordanova ES, Ameziane N, Dorsman JC, van Beek DM, van der Voorn JP, Sie D, Ylstra B, van Deurzen CH, Martens JW, Smid M, Sieuwerts AM, de Weerd V, Foekens JA, van den Ouweland AM, van Dyk E, Nederlof PM, Waisfisz Q, Meijers-Heijboer H. Massink MP, et al. Mol Oncol. 2015 Apr;9(4):877-88. doi: 10.1016/j.molonc.2014.12.012. Epub 2015 Jan 13. Mol Oncol. 2015. PMID: 25616998 Free PMC article.
Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.
Jansen MP, Sas L, Sieuwerts AM, Van Cauwenberghe C, Ramirez-Ardila D, Look M, Ruigrok-Ritstier K, Finetti P, Bertucci F, Timmermans MM, van Deurzen CH, Martens JW, Simon I, Roepman P, Linn SC, van Dam P, Kok M, Lardon F, Vermeulen PB, Foekens JA, Dirix L, Berns EM, Van Laere S. Jansen MP, et al. Mol Oncol. 2015 Jun;9(6):1218-33. doi: 10.1016/j.molonc.2015.02.006. Epub 2015 Mar 4. Mol Oncol. 2015. PMID: 25771305 Free PMC article.
221 results